Trial reportThe Journal of thoracic and cardiovascular surgery2024
Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance).
Trial report in The Journal of thoracic and cardiovascular surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 74 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Lobectomy versus sublobar resection for stage I non-small cell lung cancer: an umbrella review of evidence quality, overlap, surgical-extent heterogeneity, and survival outcomes.Frontiers in oncology · 2026Pooled it
- Could less be enough: sublobar resection vs lobectomy for clinical stage IA non-small cell lung cancer patients with visceral pleural invasion or spread through air spaces.International journal of surgery (London, England) · 2025Pooled it
- Real-time margin assessment for video-assisted thoracic surgery: A pilot clinical trial.JTCVS techniques · 2025Trial
- Article
- A structural dose-response relationship between lymph node yield and survival after anatomical segmentectomy for early-stage NSCLC: a SEER-based retrospective cohort study.Translational lung cancer research · 2026Article
- Vietnamese expert consensus on the diagnosis and multidisciplinary management of resectable non-small cell lung cancer.Translational lung cancer research · 2026Review
- Segmentectomy vs Lobectomy for Peripheral Early-Stage Non-Small Cell Lung Cancer in Patients With Radiologically High Risk Tumors.Annals of thoracic surgery short reports · 2026Article
- Association of resection type, nodal evaluation, and survival in early-stage lung squamous cell carcinoma.Journal of thoracic disease · 2026Article
- Artificial Intelligence-Driven Three-Dimensional Reconstruction System Reduced Unexpected Procedural Changes in Thoracic Surgery.Annals of surgical oncology · 2026Article
- Can the Cancer and Leukemia Group B 140503 trial support choice of segmental versus wedge resection for non-small cell lung cancer?JTCVS open · 2026Article
- Thoracoscopic Incomplete Anatomical Segmentectomy for Ground-Glass-Dominant Lung Cancer: Associations with Lower Postoperative Cough Burden and Faster Symptom Recovery.Annals of surgical oncology · 2026Article
- Machine learning-based preoperative prediction of spread through air spaces in clinical stage IA non-small cell lung cancer: a single-center study integrating clinical and CT imaging characteristics.Journal of thoracic disease · 2026Article
- Review
- Prognostic stratification of T1 lung adenocarcinoma with micropapillary or solid patterns: a cohort study.Journal of thoracic disease · 2026Article
- Function-preserving radical surgery for early-stage non-small cell lung cancer: A review of limited resection approaches.Japanese journal of clinical oncology · 2026Review
- Segmentectomy or Lobectomy in T1N0M0 Non-Small Cell Lung Carcinomas: The Prognostic Role of Histology and Vascular Invasion.Updates in surgery · 2026Article
- Wedge resection versus segmentectomy in peripheral clinical stage IA lung cancer concerning ground-glass opacity.Surgery today · 2026Article
- Survival benefit with lobectomy vs. sublobar resection in octogenarians with clinical stage IA lung cancer.Surgery today · 2026Article
- Sublobar Resection With Adequate Margin is Comparable to Lobectomy in Locoregional Recurrence.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
- When wedge resection is good enough: Survival outcomes and nodal involvement of ground-glass-dominant stage IA non-small cell lung cancer.JTCVS open · 2026Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
16 authors at 14 institutions in 2 countries.
Funding
Abstract
backgroundWe have recently reported the primary results of CALGB 140503 (Alliance), a randomized trial in patients with peripheral cT1aN0 non-small cell lung cancer (American Joint Committee on Cancer seventh) treated with either lobar resection (LR) or sublobar resection (SLR). Here we report differences in disease-free survival (DFS), overall survival (OS) and lung cancer-specific survival (LCSS) between LR, segmental resection (SR), and wedge resection (WR). We also report differences between WR and SR in terms of surgical margins, rate of locoregional recurrence (LRR), and expiratory flow rate at 6 months postoperatively.
methodsBetween June 2007 and March 2017, a total of 697 patients were randomized to LR (n = 357) or SLR (n = 340) stratified by clinical tumor size, histology, and smoking history. Ten patients were converted from SLR to LR, and 5 patients were converted from LR to SLR. Survival endpoints were estimated using the Kaplan-Maier estimator and tested by the stratified log-rank test. The Kruskal-Wallis test was used to compare margins and changes in forced expiratory volume in 1 second (FEV1) between groups, and the χ
resultsA total of 362 patients had LR, 131 had SR, and 204 had WR. Basic demographic and clinical and pathologic characteristics were similar in the 3 groups. Five-year DFS was 64.7% after LR (95% confidence interval [CI], 59.6%-70.1%), 63.8% after SR (95% CI, 55.6%-73.2%), and 62.5% after WR (95% CI, 55.8%-69.9%) (P = .888, log-rank test). Five-year OS was 78.7% after LR, 81.9% after SR, and 79.7% after WR (P = .873, log-rank test). Five-year LCSS was 86.8% after LR, 89.2% after SR, and 89.7% after WR (P = .903, log-rank test). LRR occurred in 12% after SR and in 14% after WR (P = .295). At 6 months postoperatively, the median reduction in % FEV1 was 5% after WR and 3% after SR (P = .930).
conclusionsIn this large randomized trial, LR, SR, and WR were associated with similar survival outcomes. Although LRR was numerically higher after WR compared to SR, the difference was not statistically significant. There was no significant difference in the reduction of FEV1 between the SR and WR groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.